|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neuro-protective effects of CNTF on hippocampal neurons via an unknown signal transduction pathway显示文摘In our previous study, we proposed that there may be an unknown pathway in the upper stream of the known signal transduction pathway of Ciliary neurotrophic factor (CNTF) that mediates the neuro-protective function of CNTF. In the present experiment, we observed that the neuro-protective function of the non-classic signal transduction path- way in a L-NMDA (a glutamic acid ion type receptor atagonist) induced hippocampal neuron injury model, using primary culture rat hippocampal neurons, con- tinuous photography and gp130 immunohistochemi- cal assay. The results showed that L-NMDA induced injurious reaction of hippocampal neurons, and CNTF was able to inhibit the toxic action of L-NMDA on hippocampal neurons. Additionally, when JAK/STATs in the known classic signal transduction pathway of CNTF were blocked by PTPi-2, the protective effect of CNTF against L-NMDA injury still existed. L-NMDA caused a rapid increase in the concentration of hip- pocampal intracellular free [Ca2+]i. CNTF was able to attenuate L-NMDA-induced elevation of [Ca2+]i, and blocking JAK/STATs in the known classic signal trans- duction pathway of CNTF did not affect L-NMDA- induced elevation of [Ca2+]i, indicating that, apart from the known classic signal transduction pathway, there may be some other transduction pathways for CNTF to exert the protective effect on hippocampal neurons, and this pathway is related to [Ca2+]. | LI Ping WANG Zongwen YAN Jin Li Zhaoshen JIANG Chunlei NI Xin YANG Yongji LIU Fang LU Changlin | 2006 | Chinese Science Bulletin2006，51，1： | 4 |
| 2 | Utilization and quality assessment of digestive endoscopy in China:results from 5-year consecutive nationwide surveys显示文摘Background:Worldwide,the volume and availability of digestive endoscopy have undergone dramatic development in recent years,with increasing attention on quality assurance.We investigated the utilization and quality of digestive endoscopy in China from 2015 to 2019 and developed a quantitative quality evaluation tool for medical institutions.Methods:We invited all tertiary/secondary hospitals in Chinese mainland to participate in the survey annually.The questionnaires included the personnel,annual volume,and quality indicators of endoscopy.An endoscopy quality index(EQI)was developed based on recorded quality indicators using principal component analysis to determine the relative weight.Results:From 2015 to 2019,806,1412,2644,2468,and 2541 hospitals were respectively enrolled in this study.The average annual volume of endoscopy increased from 12,445 to 16,206(1.30-fold)and from 2938 to 4255(1.45-fold)in tertiary and secondary hospitals,respectively.The most obvious growth was observed in diagnostic colonoscopy(1.44-fold for all hospitals after standardization).The proportion of early cancer among all esophageal and gastric cancers during diagnostic esophagogastroduodenoscopy increased from 12.3%(55,210/448,861)to 17.7%(85,429/482,647)and from 11.4%(69,411/608,866)to 16.9%(107,192/634,235),respectively.The adenoma detection rate of diagnostic colonoscopy increased from 14.9%(2,118,123/14,215,592)to 19.3%(3,943,203/20,431,104).The EQI model included 12 quality indicators,incorporating 64.9%(7.792/12)of the total variance into one comprehensive index.According to the EQI measurements,the quality of endoscopy was higher in tertiary hospitals and hospitals in developed areas with higher volume or more endoscopists than that in other hospitals.Conclusions:Digestive endoscopy in China has developed considerably in recent years in terms of both volume and quality.The EQI is a promising tool to quantify the quality of endoscopy at different hospitals. | Lei Xin Ye Gao Zhiyuan Cheng Tianjiao Wang Han Lin Yanan Pang Chang Sun Zengjun Fu Zhaoshen Li Xudong Ma Luowei Wang | 2022 | Chinese Medical Journal2022，135，16： | 3 |
| 3 | Body Mass Index Increases Risk for Colorectal Adenomas Based on Meta-analysis显示文摘 | Qiwen Ben Wei An Ying Jiang Xianbao Zhan Yiqi Du Quan Cai Cai Jie Gao Zhaoshen Li | 2012 | Gastroenterology2012，，4： | 3 |
| 4 | Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies显示文摘 | Qiwen Ben Maojin Xu Xiaoyan Ning Jun Liu Shangyou Hong Wen Huang Huagao Zhang Zhaoshen Li | 2011 | European Journal of Cancer2011，，13： | 2 |
| 5 | Assessment of efficacy and safety of EUS-guided biliary drainage: a systematic review显示文摘 | Kaixuan Wang Jianwei Zhu Ling Xing Yunfeng Wang Zhendong Jin Zhaoshen Li | 2015 | Gastrointestinal Endoscopy2015，，： | 2 |
| 6 | Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer显示文摘 | Liu Rui Chen Xi Du Yiqi Yao Weiyan Shen Lin Wang Cheng Hu Zhibin Zhuang Rui Ning Guang Zhang Chunni Yuan Yaozong Li Zhaoshen Zen Ke Ba Yi Zhang Chen-Yu | 2012 | Clinical Chemistry2012，，3： | 2 |
| 7 | Efficacy and Safety of Cinitapride in the Treatment of Mild to Moderate Postprandial Distress Syndrome–predominant Functional Dyspepsia显示文摘 | Yiqi Du Tun Su Xinmiao Song Jun Gao Duowu Zou Changjing Zuo Weifen Xie Bangmao Wang Zhiguang Zhang Jianming Xu Dean Tian Hesheng Luo Zhenyu Zhang Shaofeng Wang Jianping Chen Jizhong Guo Lei Gong Yanbing Ding Zhaoshen Li | 2014 | Journal of Clinical Gastroenterology2014，，4： | 1 |
| 8 | Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China—STARS Study显示文摘 | Yiqi Du Zhaoshen Li Xianbao Zhan Jie Chen Jun Gao Yanfang Gong Jianlin Ren Liping He Zhijian Zhang Xiaozhong Guo Jianshen Wu Zibin Tian Ruihua Shi Bo Jiang Dianchun Fang Youming Li | 2008 | Digestive Diseases and Sciences2008，，11： | 1 |
| 9 | Minor Endoscopic Sphincterotomy Plus Endoscopic Balloon Dilation Is An Effective and Safer Alternative for Endoscopic Sphincterotomy During ERCP in Patients with Peiampullary Diverticula and Bile Duct Stones显示文摘 | Feng Liu Feng Li Ying Zhou Meijuan Xi Duowu Zou Zhaoshen Li | 2008 | Gastrointestinal Endoscopy2008，，5： | 1 |
| 10 | Red and processed meat intake and risk of esophageal adenocarcinoma: a meta-analysis of observational studies显示文摘 | Wen Huang Yujing Han Jiping Xu Wei Zhu Zhaoshen Li | 2013 | Cancer Causes & Control2013，，1： | 1 |
| 11 | High Expression of Calcitonin Gene-Related Peptide and Substance P in Esophageal Mucosa of Patients with Non-Erosive Reflux Disease显示文摘 | Xiaorong Xu Zhaoshen Li Duowu Zou Min Yang Zhanju Liu Xingpeng Wang | 2013 | Digestive Diseases and Sciences2013，，1： | 1 |
| 12 | Damage of the interstitial cells of Cajal and myenteric neurons causing ileus in acute necrotizing pancreatitis rats显示文摘 | Hui Zhou Li Liu Yu Bai Wenbin Wu Guixiang Li Jianping Li Duowu Zou Jun Gao Zhaoshen Li | 2011 | Surgery2011，，2： | 1 |
| 13 | CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer显示文摘 | Can Xu Yunliang Sun Yunfeng Wang Yan Yan Zhengjie Shi Lei Chen Han Lin Shunli Lü Maoling Zhu Changqing Su Zhaoshen Li | 2012 | Cancer Letters2012，，： | 1 |
| 14 | Endoscopic approach to pancreatic pseudocyst, abscess and necrosis: Review on recent progress显示文摘 | Jie Chen Norio Fukami Zhaoshen Li | 2012 | Digestive Endoscopy2012，，5： | 1 |
| 15 | Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies显示文摘 | Qiwen Ben Maojin Xu Xiaoyan Ning Jun Liu Shangyou Hong Wen Huang Huagao Zhang Zhaoshen Li | 2011 | European Journal of Cancer2011，，13： | 1 |
| 16 | Effect and safety of anaprazole in the treatment of duodenal ulcers:a randomized,rabeprazole-controlled,phase Ⅲ non-inferiority study显示文摘Background:The pharmacokinetic and clinical behaviors of many proton pump inhibitors(PPIs)in peptic ulcer treatment are altered by CYP2C19 genetic polymorphisms.This non-inferiority study evaluated the efficacy and safety of the novel PPI anaprazole compared with rabeprazole.We also explored the influence of Helicobacter pylori(H.pylori)infection status and CYP2C19 polymorphism on anaprazole.Methods:In this multicenter,randomized,double-blind,double-dummy,positive-drug parallel-controlled,phase Ⅲ study,Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg+anaprazole placebo or rabeprazole placebo+anaprazole 20 mg once daily for 4 weeks.The primary efficacy endpoint was the 4-week ulcer healing rate assessed by blinded independent review.Secondary endpoints were the proportion of patients with improved overall and individual duodenal ulcer symptoms at 4 weeks.Furthermore,exploratory subgroup analysis of the primary endpoint by H.pylori status and CYP2C19 polymorphism was conducted.Adverse events were monitored for safety.Non-inferiority analysis was conducted for the primary endpoint.Results:The study enrolled 448 patients(anaprazole,n=225;rabeprazole,n=223).The 4-week healing rates were 90.9%and 93.7%for anaprazole and rabeprazole,respectively(difference,-2.8%[95%confidence interval,-7.7%,2.2%]),demonstrating non-inferiority of anaprazole to rabeprazole.Overall duodenal ulcer symptoms improved in 90.9%and 92.5%of patients,respectively.Improvement rates of individual symptoms were similar between the groups.Healing rates did not significantly differ by H.pylori status or CYP2C19 genotype for either treatment group.The incidence of treatment-emergent adverse events was similar for anaprazole(72/220,32.7%)and rabeprazole(84/219,38.4%).Conclusions:The efficacy of anaprazole is non-inferior to that of rabeprazole in Chinese patients with duodenal ulcers.Registration:ClinicalTrials.gov,NCT04215653. | Huiyun Zhu Xue Pan Li Zhang Hongxin Sun Huizhen Fan Zhongwei Pan Caibin Huang Zhenwang Shi Jin Ding Qi Wang Yiqi Du Nonghua Lyu Zhaoshen Li | 2022 | Chinese Medical Journal2022，135，24： | 1 |
| 17 | Contrast-Enhanced Harmonic Endoscopic Ultrasonography in Pancreatic Diseases显示文摘 | Can Xu Zhaoshen Li Michael Wallace Klaus M?nkemüller | 2012 | <journal-title>Diagnostic and Therapeutic Endoscopy2012，，： | 1 |
| 18 | The relationship between new-onset diabetes mellitus and pancreatic cancer risk: A case–control study显示文摘 | Qiwen Ben Quancai Cai Zhaoshen Li Yaozong Yuan Xiaoyan Ning Shangxin Deng Kaixuan Wang | 2010 | European Journal of Cancer2010，，2： | 1 |
| 19 | New insights into non-invasive screening of esophageal squamous cell carcinoma显示文摘Esophageal cancer remains a leading cause of cancer-related death worldwide.Its incidence and mortality rank seventh and sixth among all cancers in 2020[1],respectively.The geographical regions with most esophageal cancer cases and deaths include central and eastern Asia(known as the Asian esophageal cancer belt),parts of Africa,and some South American countries,with esophageal squamous cell carcinoma(ESCC)being the major histological subtype(comprising nearly 90%of cases).Due to the asymptomatic nature of early-stage lesions,more than 80%of ESCC were diagnosed at an advanced stage.This have led to an extremely poor prognosis of ESCC,with 5-year survival rates less than 20%in most countries. | Ye Gao Luowei Wang Zhaoshen Li | 2023 | Medical Review2023，3，5： | 0 |
| 20 | Engineered tumor cell-derived vaccines against cancer: The art of combating poison with poison显示文摘Tumor vaccination is a promising approach for tumor immunotherapy because it presents high specificity and few side effects.However,tumor vaccines that contain only a single tumor antigen can allow immune system evasion by tumor variants.Tumor antigens are complex and heterogeneous,and identifying a single antigen that is uniformly expressed by tumor cells is challenging.Whole tumor cells can produce comprehensive antigens that trigger extensive tumor-specific immune responses.Therefore,tumor cells are an ideal source of antigens for tumor vaccines.A better understanding of tumor cell-derived vaccines and their characteristics,along with the development of new technologies for antigen delivery,can help improve vaccine design.In this review,we summarize the recent advances in tumor cell-derived vaccines in cancer immunotherapy and highlight the different types of engineered approaches,mechanisms,administration methods,and future perspectives.We discuss tumor cell-derived vaccines,including whole tumor cell components,extracellular vesicles,and cell membrane-encapsulated nanoparticles.Tumor cell-derived vaccines contain multiple tumor antigens and can induce extensive and potent tumor immune responses.However,they should be engineered to overcome limitations such as insufficient immunogenicity and weak targeting.The genetic and chemical engineering of tumor cell-derived vaccines can greatly enhance their targeting,intelligence,and functionality,thereby realizing stronger tumor immunotherapy effects.Further advances in materials science,biomedicine,and oncology can facilitate the clinical translation of tumor cell-derived vaccines. | Xinyi Zhang Hengqing Cui Wenjun Zhang Zhaoshen Li Jie Gao | 2023 | Bioactive Materials2023，，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员